Replies to post #93871 on Biotech Values

[mcbio]

Re: PYMX

PYMX part 2... From the horse's (company's) mouth on your #2 question:

"The natural defensins don't fail. In humans they are used as a barrier and not as a systemic response. The barrier works well until bacteria get inside the body and we can't mount a systemic defense against them. Below are two papers which include more information. "

Zasloff et al, Nature, v415, pg 389-395. January 24, 2002
Tossi et al, Biopolymers, v55, pg 4-30. July 2000

Thanks so much for following up directly with the company on this. Very helpful. I'll see what I can find in those articles. The bigger point, as you noted, is that we need some hard data in infected patients. This is why I plan to wait until we get results from the upcoming Phase 2 trial of PMX-30063 before considering investing. Those results aren't expected until 1Q2011. PYMX also expects Phase 2 results from PMX-60056 during 1Q2011 so that will be a very big quarter for the company. I think it's worth it to wait for both of those results before investing, just to have strong PoC in humans for both compounds. You sacrifice potential upside in the stock by waiting on the data, but I'd rather have the peace of mind and I doubt the stock will soar on positive results from both Phase 2 trials.

[DewDiligence]

PYMX: Is that the same Michael Zasloff who founded Genaera (Magainin) and is considered by many to be a head case? Here’s a write-up on Zasloff for old time’s sake: #msg-3392247.